Journal of Blood Disorders & Transfusion

Iron Balance Management in Transfusion-Dependent Disorders: Modern Approaches to Chelation Therapy

Alf Rios^* Department of Hematology and Transfusion Medicine, Nordic University of Medical Sciences, Oslo, Norway
^*Correspondence: Alf Rios, Department of Hematology and Transfusion Medicine, Nordic University of Medical Sciences, Oslo, Norway, Email:

Received: 27-Jan-2026, Manuscript No. JBDT-26-31742; Editor assigned: 30-Jan-2026, Pre QC No. JBDT-26-31742 (PQ); Reviewed: 13-Feb-2026, QC No. JBDT-26-31742; Revised: 20-Feb-2026, Manuscript No. JBDT-26-31742 (R); Published: 27-Feb-2026, DOI: 10.4172/2155-9864.25.17.640

Description

Iron is an essential mineral required for oxygen transport, energy production, and numerous cellular functions. Although the human body depends on adequate iron stores for survival, excessive accumulation can produce significant tissue injury. Under normal physiological conditions, iron absorption from the gastrointestinal tract is carefully regulated to maintain equilibrium. However, certain inherited and acquired blood disorders can disrupt this balance, resulting in progressive iron accumulation. Patients who require repeated blood transfusions are particularly susceptible because each unit of transfused blood introduces additional iron into the body. Since humans possess no natural mechanism for active iron elimination, excess iron gradually deposits within organs and contributes to long-term complications.

Transfusion-dependent conditions such as beta-thalassemia major, sickle cell disease, myelodysplastic syndromes, and some forms of aplastic anemia frequently expose patients to chronic iron loading. Over time, iron begins to accumulate within the liver, heart, endocrine glands, and other tissues. Initially, excess iron may remain clinically silent, but continued deposition eventually interferes with organ function. Liver fibrosis, cardiac dysfunction, diabetes mellitus, delayed growth, infertility, thyroid abnormalities, and reduced quality of life may develop when iron burden remains uncontrolled for extended periods.

The biological basis of iron toxicity is linked to the formation of reactive oxygen species. When circulating iron exceeds the binding capacity of transport proteins, non-transferrin-bound iron appears in the bloodstream. This highly reactive form of iron participates in chemical reactions that generate free radicals capable of damaging proteins, lipids, and cellular membranes. Repeated exposure to oxidative injury contributes to inflammation, cellular dysfunction, and tissue destruction. Consequently, prevention and reduction of iron overload have become central objectives in the long-term management of many hematological disorders.

Chelation therapy was developed to address this challenge. Chelating agents are compounds that bind excess iron and form complexes that can be eliminated through urine, feces, or both. The introduction of iron chelators significantly improved survival among patients receiving chronic transfusion therapy. Prior to the availability of these medications, many individuals experienced early organ failure due to progressive iron accumulation. Today, effective chelation programs allow many patients to maintain healthier organ function and achieve longer life expectancy.

One of the earliest chelating agents introduced into clinical practice was deferoxamine. This medication demonstrated substantial ability to remove excess iron from the body and reduce complications associated with iron overload. Deferoxamine binds ferric iron with high affinity and promotes its elimination. Although effective, its administration presents challenges because it is typically delivered through prolonged subcutaneous or intravenous infusion. Treatment often requires several hours of infusion on multiple days each week. This schedule may affect adherence, particularly among children, adolescents, and individuals with demanding daily routines.

Despite administration difficulties, deferoxamine remains valuable in several clinical situations. It has extensive long-term safety data and may be particularly useful in patients with severe iron burden or specific clinical circumstances requiring intensive treatment. Continuous monitoring of hearing, vision, and growth parameters is generally recommended during therapy, as prolonged use may occasionally be associated with adverse effects involving these systems.

The development of oral chelators represented a substantial advancement in patient care. Deferiprone became one of the first orally administered options available for chronic iron overload management. The convenience of oral administration improved treatment acceptance among many patients. Deferiprone has demonstrated effectiveness in removing cardiac iron, an important consideration because cardiac complications remain a major cause of morbidity in transfusion-dependent populations. Improved control of myocardial iron stores may contribute to better cardiac performance and reduced risk of heart-related complications.

Another major advancement in iron overload management was the introduction of deferasirox. This once-daily oral chelator simplified treatment schedules and improved convenience for many individuals requiring lifelong therapy. Deferasirox binds iron and facilitates elimination primarily through the gastrointestinal tract. Clinical studies have demonstrated its capacity to reduce liver iron concentration and lower serum ferritin levels when used consistently.

The management of iron overload has evolved substantially over recent decades. What was once a major cause of early mortality in transfusion-dependent disorders can now be addressed through comprehensive monitoring and effective chelation therapy. Careful selection of treatment, regular assessment of iron burden, and consistent patient participation form the foundation of successful long-term care. As therapeutic options continue to expand, individuals living with chronic transfusion requirements have greater opportunities to maintain organ health, preserve functional capacity, and achieve improved overall well-being.